Evidence map›Paper›PMID 32528891›Full record

ArticleFrontiers in oncology2020

Interleukin-31 Receptor α Is Required for Basal-Like Breast Cancer Progression.

Yanling He, Xinyuan Zhang, Weijun Pan, Fang Tai, Li Liang, Jian Shi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. IL-31: State of the Art for an Inflammation-Oriented Interleukin.International journal of molecular sciences · 2022
    Pooled it
  2. Review
  3. Impact ofOncology research · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Parasitology · 2021
    Article
  9. Article
  10. Regulation of cancer stem cells in triple negative breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yanling HeDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Xinyuan ZhangDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Weijun PanDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Fang TaiDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Li LiangDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Jian ShiDepartment of Pathology, Nanfang Hospital & School of Basic Medical Science, Southern Medical University, Guangzhou, China.
Nanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BLBCBRD4IL31IL31RATwist

Identifiers

PMID32528891
PMCPMC7266966
OpenAlexW3028830068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.